C A Mullen1, H Abd El-Baki, H Samir, J J Tarrand, K V Rolston. 1. Department of Pediatrics, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. cmullen@mdanderson.org
Abstract
GOALS: Candidemia is a serious infection that can severely complicate the care of children with cancer. We sought to determine the spectrum of Candida species in children with cancer, since effective therapy may depend on the species involved. PATIENTS AND METHODS: A retrospective review of candidemia episodes in our pediatric oncology patients over a 9-year period was conducted. During this period azole prophylaxis was not routine in this group. RESULTS: 38 episodes of candidemia were identified: C. albicans 29%, C. tropicalis 26%, C. parapsilosis 24%, C. krusei 8%, C. glabrata 8%, and C. lusitaniae 5%. Non-albicans Candida was common in patients not receiving azole prophylaxis. Species typically susceptible to azoles were common among patients not using azoles. Death attributed to the fungal infection occurred in 21% of episodes, with nearly all the deaths occurring in patients with C. albicans and C. tropicalis. CONCLUSIONS: C. albicans is not the predominant species in pediatric oncology patients experiencing candidemia, even in azole-naive patients.
GOALS: Candidemia is a serious infection that can severely complicate the care of children with cancer. We sought to determine the spectrum of Candida species in children with cancer, since effective therapy may depend on the species involved. PATIENTS AND METHODS: A retrospective review of candidemia episodes in our pediatric oncology patients over a 9-year period was conducted. During this period azole prophylaxis was not routine in this group. RESULTS: 38 episodes of candidemia were identified: C. albicans 29%, C. tropicalis 26%, C. parapsilosis 24%, C. krusei 8%, C. glabrata 8%, and C. lusitaniae 5%. Non-albicans Candida was common in patients not receiving azole prophylaxis. Species typically susceptible to azoles were common among patients not using azoles. Death attributed to the fungal infection occurred in 21% of episodes, with nearly all the deaths occurring in patients with C. albicans and C. tropicalis. CONCLUSIONS:C. albicans is not the predominant species in pediatric oncology patients experiencing candidemia, even in azole-naive patients.
Authors: A L Colombo; M Nucci; R Salomão; M L Branchini; R Richtmann; A Derossi; S B Wey Journal: Diagn Microbiol Infect Dis Date: 1999-08 Impact factor: 2.803
Authors: C Girmenia; P Martino; F De Bernardis; G Gentile; M Boccanera; M Monaco; G Antonucci; A Cassone Journal: Clin Infect Dis Date: 1996-09 Impact factor: 9.079
Authors: Gerald P Bodey; Masoud Mardani; Hend A Hanna; Maha Boktour; Jalal Abbas; Essam Girgawy; Ray Y Hachem; Dimitrios P Kontoyiannis; Issam I Raad Journal: Am J Med Date: 2002-04-01 Impact factor: 4.965
Authors: J H van Burik; W Leisenring; D Myerson; R C Hackman; H M Shulman; G E Sale; R A Bowden; G B McDonald Journal: Medicine (Baltimore) Date: 1998-07 Impact factor: 1.889
Authors: M A Slavin; B Osborne; R Adams; M J Levenstein; H G Schoch; A R Feldman; J D Meyers; R A Bowden Journal: J Infect Dis Date: 1995-06 Impact factor: 5.226
Authors: John J Hawkshead; Russell B Van Dyke; Susan E Hassig; Larry S Webber; Rodolfo E Begue Journal: Infect Drug Resist Date: 2016-04-18 Impact factor: 4.003